Lymphocyte regulation of neuropeptide gene expression after neuronal injury

Armstrong BD, Hu Z, Abad C, Yamamoto M, Rodríguez WI, Cheng J, Tam J, Gomariz RP, Patterson PH, Waschek JA.

J Neurosci Res. 2003 Oct 15;74(2):240-7.

PACAP in immunity and inflammation

Delgado M, Abad C, Martínez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP.

Ann N Y Acad Sci. 2003 May;992:141-57.

Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease

Abad C, Martínez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP.

Gastroenterology. 2003 Apr;124(4):961-71.

Pituitary adenylate-cyclase-activating polypeptide expression in the immune system

Abad C, Martínez C, Leceta J, Juarranz MG, Delgado M, Gomariz RP.

Neuroimmunomodulation. 2002-2003;10(3):177-86.

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia

Delgado M, Leceta J, Ganea D.

J Leukoc Biol. 2003 Jan;73(1):155-64.

VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal

Gutiérrez-Cañas I, Rodríguez-Henche N, Bolaños O, Carmena MJ, Prieto JC, Juarranz MG.

Br J Pharmacol. 2003 Jul;139(5):1050-8. PDF

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells

Delgado M, Leceta J, Ganea D.

FASEB J. 2002 Nov;16(13):1844-6.

Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases

Delgado M, Abad C, Martínez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J.

J Mol Med (Berl). 2002 Jan;80(1):16-24.

Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor

Martínez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodríguez-Henche N, Brabet P, Leceta J, Gomariz RP.

Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1053-8. PDF

Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy

Abad C, Martínez C, Leceta J, Gomariz RP, Delgado M.

J Immunol. 2001 Sep 15;167(6):3182-9. PDF

Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

Delgado M, Abad C, Martínez C, Leceta J, Gomariz RP.

Nat Med. 2001 May;7(5):563-8.

Immunology of VIP: a review and therapeutical perspectives

Gomariz RP, Martínez C, Abad C, Leceta J, Delgado M.

Curr Pharm Des. 2001 Jan;7(2):89-111.

Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors

Juarranz MG, Bolaños O, Gutiérrez-Cañas I, Lerner EA, Robberecht P, Carmena MJ, Prieto JC, Rodríguez-Henche N.

Cell Signal. 2001 Dec;13(12):887-94.

Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure

Vertongen P, Solano RM, Juarranz MG, Perret J, Waelbroeck M, Robberecht P.

Peptides. 2001 Sep;22(9):1363-70.

Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation

Juarranz MG, Bodega G, Prieto JC, Guijarro LG.

Prostate. 2001 Jun 1;47(4):285-92.

Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction

Solano RM, Langer I, Perret J, Vertongen P, Juarranz MG, Robberecht P, Waelbroeck M.

J Biol Chem. 2001 Jan 12;276(2):1084-8.